ALLOGENE THERAPEUTICS INC (ALLO) Stock Fundamental Analysis

NASDAQ:ALLO • US0197701065

2.405 USD
+0.11 (+5.02%)
Last: Feb 25, 2026, 01:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ALLO scores 3 out of 10 in our fundamental rating. ALLO was compared to 521 industry peers in the Biotechnology industry. While ALLO seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ALLO had negative earnings in the past year.
  • ALLO had a negative operating cash flow in the past year.
  • ALLO had negative earnings in each of the past 5 years.
  • In the past 5 years ALLO always reported negative operating cash flow.
ALLO Yearly Net Income VS EBIT VS OCF VS FCFALLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • ALLO has a Return On Assets (-48.21%) which is in line with its industry peers.
  • ALLO has a Return On Equity (-67.24%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -48.21%
ROE -67.24%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ALLO Yearly ROA, ROE, ROICALLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • ALLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLO Yearly Profit, Operating, Gross MarginsALLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALLO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALLO has more shares outstanding
  • ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALLO Yearly Shares OutstandingALLO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ALLO Yearly Total Debt VS Total AssetsALLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -4.86, we must say that ALLO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.86, ALLO is not doing good in the industry: 62.00% of the companies in the same industry are doing better.
  • ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.86
ROIC/WACCN/A
WACC8.67%
ALLO Yearly LT Debt VS Equity VS FCFALLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 8.19 indicates that ALLO has no problem at all paying its short term obligations.
  • ALLO has a better Current ratio (8.19) than 74.86% of its industry peers.
  • ALLO has a Quick Ratio of 8.19. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
  • ALLO has a better Quick ratio (8.19) than 74.86% of its industry peers.
Industry RankSector Rank
Current Ratio 8.19
Quick Ratio 8.19
ALLO Yearly Current Assets VS Current LiabilitesALLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 33.78% over the past year.
  • Looking at the last year, ALLO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
  • The Revenue for ALLO have been decreasing by -91.70% on average. This is quite bad
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 15.62% on average over the next years. This is quite good.
  • ALLO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 463.49% yearly.
EPS Next Y27.78%
EPS Next 2Y15.22%
EPS Next 3Y11.07%
EPS Next 5Y15.62%
Revenue Next Year-100%
Revenue Next 2Y-44.9%
Revenue Next 3Y654.21%
Revenue Next 5Y463.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALLO Yearly Revenue VS EstimatesALLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
ALLO Yearly EPS VS EstimatesALLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ALLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ALLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLO Price Earnings VS Forward Price EarningsALLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLO Per share dataALLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.22%
EPS Next 3Y11.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALLO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (2/25/2026, 1:03:57 PM)

2.405

+0.11 (+5.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners50.51%
Inst Owner Change0.91%
Ins Owners6.85%
Ins Owner Change-0.35%
Market Cap540.48M
Revenue(TTM)N/A
Net Income(TTM)-212.01M
Analysts82.86
Price Target7.53 (213.1%)
Short Float %11.84%
Short Ratio4.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.05%
Min EPS beat(2)16.55%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)14.25%
Min EPS beat(4)5.26%
Max EPS beat(4)17.64%
EPS beat(8)8
Avg EPS beat(8)9.76%
EPS beat(12)11
Avg EPS beat(12)9.95%
EPS beat(16)15
Avg EPS beat(16)10.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.76%
PT rev (3m)-2.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.33%
EPS NY rev (1m)-0.73%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.21%
ROE -67.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.19
Quick Ratio 8.19
Altman-Z -4.86
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)17.35%
Cap/Depr(5y)225.27%
Cap/Sales(3y)2304.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
EPS Next Y27.78%
EPS Next 2Y15.22%
EPS Next 3Y11.07%
EPS Next 5Y15.62%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-44.9%
Revenue Next 3Y654.21%
Revenue Next 5Y463.49%
EBIT growth 1Y56.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.4%
EBIT Next 3Y2.25%
EBIT Next 5Y4.47%
FCF growth 1Y36.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.67%
OCF growth 3YN/A
OCF growth 5YN/A

ALLOGENE THERAPEUTICS INC / ALLO FAQ

What is the fundamental rating for ALLO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALLO.


What is the valuation status of ALLOGENE THERAPEUTICS INC (ALLO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALLOGENE THERAPEUTICS INC (ALLO). This can be considered as Overvalued.


Can you provide the profitability details for ALLOGENE THERAPEUTICS INC?

ALLOGENE THERAPEUTICS INC (ALLO) has a profitability rating of 1 / 10.


How financially healthy is ALLOGENE THERAPEUTICS INC?

The financial health rating of ALLOGENE THERAPEUTICS INC (ALLO) is 6 / 10.